Mar 2, 2026 06:43AM
Mar 1, 2026 12:30PM
Mar 1, 2026 12:30PM
Feb 27, 2026 06:54AM
Feb 26, 2026 12:21PM
Feb 26, 2026 07:00AM
Feb 18, 2026 04:30PM RBC Capital Starts Rhythm Pharmaceuticals (RYTM) at Outperform; 'Set' Up to Hit High Notes in Rare Obesity'
Jan 9, 2026 01:08PM
Jan 9, 2026 08:02AM
Jan 9, 2026 08:00AM
Dec 17, 2025 06:45AM
Nov 7, 2025 02:06PM
Nov 7, 2025 07:30AM
Nov 7, 2025 07:30AM Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Nov 4, 2025 07:00AM
Sep 29, 2025 06:56AM
Sep 25, 2025 06:50AM
Sep 25, 2025 05:12AM
Sep 25, 2025 04:02AM
Sep 24, 2025 03:42PM
Aug 20, 2025 04:01PM FDA accepts Rhythm Pharmaceuticals' setmelanotide filing for rare obesity
Aug 20, 2025 04:01PM
Dec 19, 2024 09:42AM
Dec 3, 2024 06:00AM
Nov 13, 2024 06:30PM
Nov 13, 2024 06:30PM
Nov 5, 2024 04:01PM
Aug 26, 2024 08:02AM Rhythm Pharmaceuticals (RYTM) Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE in Patients as Young as 2 years old
Aug 26, 2024 08:02AM
Jun 13, 2022 08:00AM
Jun 13, 2022 08:00AM
Jun 13, 2022 08:00AM
Jun 13, 2022 08:00AM
Jun 2, 2022 04:01PM
Jun 2, 2022 04:01PM Rhythm Pharmaceuticals Announces New Employment Inducement Grants
May 5, 2022 04:01PM
May 5, 2022 04:01PM
May 4, 2022 08:00AM
May 4, 2022 08:00AM
May 3, 2022 07:00AM
May 3, 2022 07:00AM
May 2, 2022 08:00AM Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting
May 2, 2022 08:00AM
Apr 26, 2022 08:00AM
Apr 26, 2022 08:00AM
Apr 8, 2022 08:00AM
Apr 8, 2022 08:00AM
Apr 6, 2022 08:02AM
Apr 6, 2022 08:00AM Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity
Apr 6, 2022 08:00AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All